Overview

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

Status:
Terminated
Trial end date:
2020-05-22
Target enrollment:
Participant gender:
Summary
This study will determine the highest dose of L-DOS47 that can be given in combination with vinorelbine/cisplatin, evaluate safety and tolerability of L-DOS47 when given in combination with vinorelbine/cisplatin, and assess how effective this combination is in treating patients with lung adenocarcinoma compared to patients who are given vinorelbine/cisplatin alone.
Phase:
Phase 2
Details
Lead Sponsor:
Helix BioPharma Corporation
Collaborator:
KCR S.A.
Treatments:
Cisplatin
Immunoconjugates
Vinorelbine